1240427-94-4

Basic information

• Product Name: C₃₆H₄₄N₆O₅
• Synonyms: C₃₆H₄₄N₆O₅
• CAS NO: 1240427-94-4
• Molecular Weight: 640.783
• Mol File: 1240427-94-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: C₃₆H₄₄N₆O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₆H₄₄N₆O₅(1240427-94-4)
• EPA Substance Registry System: C₃₆H₄₄N₆O₅(1240427-94-4)

Safety Data

• Hazardous Substances Data: 1240427-94-4(Hazardous Substances Data)

Upstream product

• 4073-80-7 bis(p-bromoacetylphenyl) ether 
• 1240427-81-9 (2S,2'S)-1-tert-butyl '2,2-2,2'-(4,4'-oxybis(4,1-phenylene))bis(2-oxo-ethane-2,1-diyl)dipyrrolidine-1,2-dicarboxylate 
• 101-84-8 diphenylether 
• 631-61-8 ammonium acetate 
• 27391-25-9 bis-(4-glycyl-phenyl)-ether ; dihydrochloride 
• 14387-30-5 dimethyl 4,4'-oxydibenzoate 
• 3030-53-3 4,4'-bis(chloroacetyl)diphenyl ether 
• 1250935-62-6 C₃₆H₄₆N₄O₉ 

Downstream Products

• 1256383-69-3 dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(oxybis(4,1-phenylene))bis(1H-imidazole5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate 
• 1251195-93-3 (S)-5,5'-(4,4'-oxybis(4,1-phenylene))bis(2-((S)-pyrrolidin-2-yl)-1H-imidazole) 

Relevant articles and documents

POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and othe

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.